ALBIREO PHARMA INC/ US09064M2044 /
2016-10-14 12:00:00 AM | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
0.56USD | - | 4,454 Turnover: - |
0.56Bid Size: - | 0.58Ask Size: - | 0.56 | 0.55 |
GlobeNewswire
03-18
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
GlobeNewswire
2023-11-01
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
GlobeNewswire
2023-10-23
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswire
2022-03-29
Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Sy...
GlobeNewswire
2022-02-14
Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare...
GlobeNewswire
2021-12-02
Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer
GlobeNewswire
2021-11-12
Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Reveal of New Next Gen...